Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, T-Cell, Peripheral 20Lymphoma, T-Cell, Cutaneous 19Lymphoma, T-Cell 17Lymphoma 16Lymphoma, Large B-Cell, Diffuse 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large-Cell, Anaplastic 8Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Lung Neoplasms 3Hematologic Neoplasms 3

Interventions

Carboplatin 31Paclitaxel 26Radiotherapy 23Bevacizumab 19Erlotinib Hydrochloride 16Cisplatin 14Gemcitabine 12Gefitinib 11Docetaxel 11Taxes 9Pemetrexed 9Etoposide 5pegfilgrastim 4Radiotherapy, Conformal 4Radiation 4Neoadjuvant Therapy 4Chemotherapy, Adjuvant 4Cetuximab 4Vinorelbine 3Amplified Fragment Length Polymorphism Analysis 3Topotecan 2Thalidomide 2Sorafenib 2Radiosurgery 2Pharmacogenomic Testing 2Nivolumab 2Magnetic Resonance Spectroscopy 2Irinotecan 2Gene Expression Profiling 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Bronchiolo-Alveolar × romidepsin × Clear all
NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

University of Texas Southwestern Medical Center

Phase 1 Completed
17 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡